
1. immune netw. 2014 aug;14(4):207-18. doi: 10.4110/in.2014.14.4.207. epub 2014 aug 
22.

enhancing cell immune responses b cell-based therapeutic vaccine against
chronic virus infection.

kim mk(1), lee a(1), hwang yk(2), kang cy(3), ha sj(1).

author information: 
(1)system immunology laboratory, department biochemistry, college life
science biotechnology, yonsei university, seoul 120-749, korea.
(2)cell therapy team, mogam biotechnology institute, yongin 446-799, korea.
(3)college pharmacy, seoul national university, seoul 110-799, korea.

chronic virus infection leads functional impairment dendritic cells
(dcs) well cells, limiting clinical usefulness dc-based
therapeutic vaccine chronic virus infection. meanwhile, b cells been
known maintain ability differentiate plasma cells producing antibodies 
even chronic virus infection. previously, α-galactosylceramide (αgc) and
cognate peptide-loaded b cells comparable dcs priming peptide-specific
cd8(+) cells antigen presenting cells (apcs). here, investigated whether 
b cells activated αgc improve virus-specific cell immune responses
instead dcs chronic virus infection. found comparable b
cells isolated naïve mice, chronic b cells isolated chronically
infected mice lymphocytic choriomeningitis virus (lcmv) clone 13 (cl13)
after αgc-loading could activate cd1d-restricted invariant natural killer t
(inkt) cells produce effector cytokines upregulate co-stimulatory
molecules naïve chronically infected mice. similar naïve b cells, 
chronic b cells efficiently primed lcmv glycoprotein (gp) 33-41-specific p14
cd8(+) cells vivo, thereby allowing proliferation functional cd8(+) t
cells. importantly, αgc cognate epitope-loaded chronic b cells were
transferred chronically infected mice, mice showed significant
increase population epitope-specific cd8(+) cells accelerated
control viremia. therefore, studies demonstrate reciprocal activation
between αgc-loaded chronic b cells inkt cells strengthen virus-specific t
cell immune responses, providing effective regimen autologous b cell-based 
therapeutic vaccine treat chronic virus infection.

doi: 10.4110/in.2014.14.4.207 
pmcid: pmc4148491
pmid: 25177253 

